Skip to main content
Regulatory Update

Japan PMDA Clarifies Concordance Evidence for Oncology CDx

Two Japanese PMDA notices dated 11 November 2026 address concordance for DNA-sequencer companion diagnostics and for diagnostics tied to trials that enrolled patients using site-selected tests.

Published on:
November 19, 2026

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) posted provisional English translations on 19 November 2026 of two Early Consideration notices dated 11 November 2026. The Japanese originals are authoritative. The two companion notices describe circumstances in which companion diagnostic (CDx) developers may propose evidence other than a direct concordance study. They are technical recommendations. Each approach depends on the evidence for the proposed test and its intended use.

DNA-sequencer tests with an existing comparator

In the first notice (English translation, sections 2–3), PMDA addresses oncology CDx based on DNA sequencers when a clinical trial assay or an original CDx uses the same technology. PMDA says a direct study may be omitted if the developer can explain concordance in the limit of detection and criteria for positivity using a representative mutation. Analytical performance must be established. A test for an analytical target or cancer type outside the previously approved scope still needs a separate analytical performance evaluation.

The notice assumes access to published positivity criteria and limit of detection or clinical cut-off for the trial assay, along with appropriate information sharing between developers. When direct concordance is omitted, PMDA considers it appropriate for the CDx package insert to explain the basis for the evaluation and state that direct concordance with the trial assay or original CDx was unconfirmed. It says a similar approach may apply to a polymerase chain reaction test in a case of particularly high medical need, when the target mutation is extremely rare and a concordance study is difficult.

Pivotal trials that used site-selected tests

In the second notice (English translation, sections 2–4), PMDA considers drugs that demonstrated efficacy and safety in populations enrolled with local laboratory tests. One option is to examine efficacy and safety by assay principle. If the evidence supports use of an assay principle for patient selection, the developer may be able to file an approval or partial-change application for a test using that principle without demonstrating concordance with a particular test. The developer needs to justify the proposed test's analytical performance and may need to show that it meets test requirements specified in the trial protocol.

PMDA says a test approved using this approach still qualifies as a CDx. It considers it desirable for the CDx insert to say that direct concordance with the pivotal-trial test was unconfirmed. PMDA considers it desirable to list mutations detected at enrollment and those the protocol defined as positive in the corresponding drug’s package insert.

What to bring to a PMDA consultation

The notices recommend early consultation, by the consultation on the proposed pivotal-trial design at the latest. They add the following to the materials described in PMDA's 5 October 2026 notice on parallel development.

Development situationMaterials PMDA identifies
DNA-sequencer test with an existing comparatorAssay principles and differences, published comparator thresholds and positivity criteria, the proposed evaluation method, and what will be disclosed to users and developers
Trial using site-selected testsAs available, the trial summary and inclusion criteria, the list of enrollment tests with principles, specimen types and patient counts, protocol test requirements, and details of the proposed CDx

Pure Global analysis. For a sequencing program, verify that comparator thresholds and positivity definitions will be accessible before proposing a study design. For a program using site-selected tests, agree with trial sites on how to record the test and assay principle for each enrollment. Those records can support an analysis by assay principle if you intend to discuss that approach with PMDA.

Read more

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Contact us